TABLE 2.
Predicted and observed outcomes associated with different piperacillin-tazobactam exposures
| Isolate | Tazobactam dose (g)a | %fT>MICi | Outcomeb |
|
|---|---|---|---|---|
| Predicted | Observed | |||
| Kp3 | 0.5 | 39.6 | NA | Regrowth |
| 1 | 51.6 | NA | Regrowth | |
| 1.5 | 55.1 | NA | Suppression | |
| 2 | 58.6 | NA | Suppression | |
| EcF65 | 0.5 | 43.8 | Regrowth | Regrowth |
| 1 | 60.0 | Suppression | Suppression | |
| 1.5 | 65.0 | Suppression | Suppression | |
| KpK91 | 0.5 | 44.5 | Regrowth | Regrowth |
| 1 | 50.9 | Regrowth | ND | |
| 1.5 | 50.9 | Regrowth | ND | |
| 2 | 50.9 | Regrowth | ND | |
| 4 | 50.9 | Regrowth | Regrowth | |
| Kp2301 | 0.5 | 13.5 | Regrowth | Regrowth |
| 1 | 19.9 | Regrowth | ND | |
| 1.5 | 25.5 | Regrowth | ND | |
| 2 | 29.8 | Regrowth | ND | |
| 4 | 36.8 | Regrowth | Regrowth | |
a
Coadministered with piperacillin, 4 g every 8 h.
b
NA, not applicable; ND, not determined.